C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.670
+0.080 (3.09%)
At close: Dec 5, 2025, 4:00 PM EST
2.642
-0.028 (-1.05%)
After-hours: Dec 5, 2025, 7:59 PM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 8.50, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 218.35% from the current stock price of 2.67.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 23, 2025.
Analyst Ratings
The average analyst rating for C4 Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +274.53% | Sep 23, 2025 |
| Barclays | Barclays | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +274.53% | Sep 23, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +124.72% | Sep 22, 2025 |
| Barclays | Barclays | Buy Initiates $8 | Buy | Initiates | $8 | +199.63% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
32.83M
from 35.58M
Decreased by -7.73%
Revenue Next Year
22.03M
from 32.83M
Decreased by -32.90%
EPS This Year
-1.56
from -1.52
EPS Next Year
-1.44
from -1.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.8M | 42.0M | ||||
| Avg | 32.8M | 22.0M | ||||
| Low | 27.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.2% | 27.9% | ||||
| Avg | -7.7% | -32.9% | ||||
| Low | -22.9% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.26 | -0.89 | ||||
| Avg | -1.56 | -1.44 | ||||
| Low | -1.95 | -2.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.